US regulators have approved Trinity Biotech’s system for diagnosing and monitoring diabetes, paving the way for sales in one of the world’s biggest markets.

Trinity said the US Food and Drug Administration has approved its Premier Hb9210 system. The Irish firm said the decision will allow the instrument to be launched and sold in the US market. It is estimated 13 per cent of US adults have diabetes.